<DOC>
	<DOCNO>NCT00975065</DOCNO>
	<brief_summary>The study design trial open-label , randomize , multi-center , parallel-group study .</brief_summary>
	<brief_title>Galvus Met Phase 4 Study : Study Evaluate Efficacy Safety Early Combination Vildagliptin Metformin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>- The progressive nature T2DM require use combination therapy many patient time achieve maintain glycemic control . Early combination , compare maximal dose monotherapy , could effective lower glycemia well tolerability . - Vildagliptin new oral antidiabetic drug act potent selective inhibitor dipeptidyl peptidase-4 ( DPP-4 ) , enzyme responsible rapid degradation circulate glucagon-like peptide-1 . Vildagliptin improve islet function mechanism increase plasma level active form incretin hormone , GLP-1 GIP . - Metformin improve hyperglycemia primarily suppression hepatic gluconeogenesis well enhancement peripheral glucose update . Metformin commonly prescribe first-line antidiabetic drug worldwide , due progressive worsen blood glucose control natural history type 2 diabetes , combination therapy usually become necessary . - Thus combination therapy complimentary action mechanism could effective titration monotherapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients Type 2 Diabetes Mellitus inadequately control ( baseline A1c 7.0~11.0 % ) metformin monotherapy ( 1500mg metformin ) â‰¥ 2 month baseline visit Age 1880 year Body Mass Index 1840 kg/m2 Type 1 diabetes Myocardial Infarction , Unstable Angina , Coronary Artery Bypass Graft within previous 6 month Congestive Heart Failure ( III NYHA class IV ) Liver disease cirrhosis Chronic Active Hepatitis History Lacticacidemia Use Oral Antidiabetic Drug Metformin within 2 month Use insulin screen visit ALT AST &gt; 3 time upper limit Normal range Creatinine &gt; 1.5 mg/dl Other situation ( pregnant lactating female , history drug alcohol abuse , nightshift worker , clinically significant laboratory abnormality screen medical condition would affect completion outcome study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Galvus</keyword>
</DOC>